---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-047880"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2023-10-11T23:59:59+00:00"
generated_at: "2026-06-10T01:46:08.227916+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve stock issuance on conversion of Series A Preferred for Pionyr acquisition

## Summary
- Special meeting on October 11, 2023; 37,464,898 shares outstanding.
- Proposal 1 (stock issuance on conversion of Series A Preferred) approved: 25,681,604 for, 12,086 against, 1,156 abstain.
- 1,647,531 shares excluded from Nasdaq vote but counted under Delaware law.
- Proposal 2 (adjournment if needed) approved: 26,947,409 for, 394,239 against, 729 abstain.

## SEC filing metadata
- accession: 0001140361-23-047880
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2023-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000114036123047880/0001140361-23-047880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000114036123047880/ef20012370_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-047880
- JSON: https://secwatch.observer/filing/0001140361-23-047880.json
- Plain text: https://secwatch.observer/filing/0001140361-23-047880.txt

## Key facts
- Shareholder Votes
  ImageneBio, Inc. shareholders approved Issuance of common stock upon conversion of Series A Non-Voting Convertible Preferred Stock in connection with the acquisition of Pionyr Immunotherapeutics, Inc. at the 2023-10-11 meeting.
  - Outcome: passed
  - Meeting: 2023-10-11
  source text: The Company’s stockholders approved, in accordance with Nasdaq Listing Rule 5635(a), the issuance of the Company’s common stock, par value $0.001 per share (“Common Stock”), upon conversion of the Company’s Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (“Proposal No. 1"), issued in connection with the acquisition of Pionyr Immunotherapeutics, Inc. (the “Acquisition”). The votes cast at the Special Meeting were as follows: For Against Abstain 25,681,604 12,086 1,156
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000114036123047880/0001140361-23-047880-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.